CONTEXT: Advanced Glycation End-Products (AGEs) are signaling proteins associated to several vascular and @entity16 in @entity6 and non- @entity6 @entity1 . AGEs proved to be a marker of negative outcome in both @entity6 management and surgical procedures in these @entity1 . The reported role of AGEs prompted the development of pharmacological inhibitors of their effects, giving rise to a number of both preclinical and clinical studies. Clinical trials with anti-AGEs drugs have been gradually developed and this review aimed to summarize most relevant reports. EVIDENCE ACQUISITION: Evidence acquisition process was performed using PubMed and ClinicalTrials.gov with manually checked articles. RESULTS: Pharmacological approaches in @entity1 include @entity5118 , @entity2766 , @entity26424 , @entity7774 converting enzyme inhibitors, angiotensin receptor blockers, statin, @entity39912 (alagebrium) and @entity12721 . The most recent promising anti-AGEs agents are statins, @entity39912 and @entity12721 . The role of AGEs in disease and new compounds interfering with their effects are currently under investigation in preclinical settings and these newer anti-AGEs drugs would undergo clinical evaluation in the next years. Compounds with anti-AGEs activity but still not available for clinical scenarios are @entity68443 , @entity68444 , @entity68445 , @entity39107 , @entity56854 , sRAGE and @entity32704 . CONCLUSIONS: Despite most studies confirm the efficacy of these pharmacological approaches, other reports produced conflicting evidences; in almost any case, these drugs were well tolerated. At present, AGEs measurement has still not taken a precise role in clinical practice, but its relevance as a marker of disease has been widely shown; therefore, it is important for clinicians to understand the value of new cardiovascular risk factors. Findings from the current and future clinical trials may help in determining the role of AGEs and the benefits of anti-AGEs treatment in @entity65 .

Pharmacologic Approaches Against Advanced Glycation End Products (AGEs) in XXXX .

@entity1 :: ('9606', 'Species') :: ['humans', 'patients'] @entity5118 :: ('MESH:C004479', 'Chemical') :: ['aminoguanidine'] @entity6 :: ('MESH:D003920', 'Disease') :: ['diabetic', 'diabetes'] @entity7774 :: ('MESH:D000809', 'Chemical') :: ['angiotensin'] @entity68443 :: ('MESH:C468887', 'Chemical') :: ['ALT-946'] @entity16 :: ('MESH:D009422', 'Disease') :: ['neurological complications'] @entity68445 :: ('MESH:C059511', 'Chemical') :: ['tenilsetam'] @entity68444 :: ('MESH:C105739', 'Chemical') :: ['OPB-9195'] @entity39107 :: ('MESH:C485003', 'Chemical') :: ['LR-90'] @entity12721 :: ('MESH:D045162', 'Chemical') :: ['thiazolidinediones'] @entity39912 :: ('MESH:C406794', 'Chemical') :: ['ALT-711', 'alagebrium'] @entity56854 :: ('MESH:C527492', 'Chemical') :: ['TM2002'] @entity2766 :: ('MESH:D011733', 'Chemical') :: ['pyridoxamine'] @entity32704 :: ('5176', 'Gene') :: ['PEDF'] @entity65 :: ('MESH:D002318', 'Disease') :: ['cardiovascular disease'] @entity26424 :: ('MESH:C013835', 'Chemical') :: ['benfotiamine']
@entity65 :: (MESH:D002318,Disease) :: ['Diabetic Cardiovascular Disease']
